Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Design and synthesis of N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5- methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]glycine [Muraglitazar/BMS-298585], a novel peroxisome proliferator-activated receptor alpha/gamma dual agonist with efficacious glucose and lipid-lowering activities.

Literature DB >> 15771468

Design and synthesis of N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5- methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]glycine [Muraglitazar/BMS-298585], a novel peroxisome proliferator-activated receptor alpha/gamma dual agonist with efficacious glucose and lipid-lowering activities.

Pratik V Devasthale¹, Sean Chen, Yoon Jeon, Fucheng Qu, Chunning Shao, Wei Wang, Hao Zhang, Michael Cap, Dennis Farrelly, Rajasree Golla, Gary Grover, Thomas Harrity, Zhengping Ma, Lisa Moore, Jimmy Ren, Ramakrishna Seethala, Lin Cheng, Paul Sleph, Wei Sun, Aaron Tieman, John R Wetterau, Arthur Doweyko, Gamini Chandrasena, Shu Y Chang, W Griffith Humphreys, Vito G Sasseville, Scott A Biller, Denis E Ryono, Fred Selan, Narayanan Hariharan, Peter T W Cheng.

Abstract

Muraglitazar/BMS-298585 (2) has been identified as a non-thiazolidinedione PPAR alpha/gamma dual agonist that shows potent activity in vitro at human PPARalpha (EC(50) = 320 nM) and PPARgamma(EC(50) = 110 nM). Compound 2 shows excellent efficacy for lowering glucose, insulin, triglycerides, and free fatty acids in genetically obese, severely diabetic db/db mice and has a favorable ADME profile. Compound 2 is currently in clinical development for the treatment of type 2 diabetes and dyslipidemia.

Entities: Chemical Disease Gene Species

Mesh：

Substances：

Year: 2005 PMID： 15771468 DOI： 10.1021/jm0496436

Source DB: PubMed Journal: J Med Chem ISSN： 0022-2623 Impact factor: 7.446

Keyword Cloud
Cited

12 in total

1. Discovery and Preclinical Evaluation of BMS-711939, an Oxybenzylglycine Based PPARα Selective Agonist.

Authors: Yan Shi; Jun Li; Lawrence J Kennedy; Shiwei Tao; Andrés S Hernández; Zhi Lai; Sean Chen; Henry Wong; Juliang Zhu; Ashok Trehan; Ngiap-Kie Lim; Huiping Zhang; Bang-Chi Chen; Kenneth T Locke; Kevin M O'Malley; Litao Zhang; Rai Ajit Srivastava; Bowman Miao; Daniel S Meyers; Hossain Monshizadegan; Debra Search; Denise Grimm; Rongan Zhang; Thomas Harrity; Lori K Kunselman; Michael Cap; Jodi Muckelbauer; Chiehying Chang; Stanley R Krystek; Yi-Xin Li; Vinayak Hosagrahara; Lisa Zhang; Pathanjali Kadiyala; Carrie Xu; Michael A Blanar; Robert Zahler; Ranjan Mukherjee; Peter T W Cheng; Joseph A Tino
Journal: ACS Med Chem Lett Date: 2016-04-04 Impact factor: 4.345

Review 2. PPARgamma as a new therapeutic target in inflammatory bowel diseases.

Authors: L Dubuquoy; C Rousseaux; X Thuru; L Peyrin-Biroulet; O Romano; P Chavatte; M Chamaillard; P Desreumaux
Journal: Gut Date: 2006-09 Impact factor: 23.059

3. Discovery of a Novel Selective Dual Peroxisome Proliferator-Activated Receptor α/δ Agonist for the Treatment of Primary Biliary Cirrhosis.

Authors: Zhigan Jiang; Xing Liu; Zhiliang Yuan; Haiying He; Jing Wang; Xiao Zhang; Zhen Gong; Lijuan Hou; Liang Shen; Fengxun Guo; Jiliang Zhang; Jianhua Wang; Deming Xu; Zhuowei Liu; Haijun Li; Xiaoxin Chen; Chaofeng Long; Jian Li; Shuhui Chen
Journal: ACS Med Chem Lett Date: 2019-06-24 Impact factor: 4.345

4. Comparative gene expression profiles induced by PPARγ and PPARα/γ agonists in human hepatocytes.

Authors: Alexandra Rogue; Carine Lambert; Rozenn Jossé; Sebastien Antherieu; Catherine Spire; Nancy Claude; André Guillouzo
Journal: PLoS One Date: 2011-04-18 Impact factor: 3.240

5. Antitumor activity of a novel series of alpha-aryloxy-alpha-methylhydrocinnamic acid derivatives as PPAR gamma agonists against a panel of human cancer cell lines.

Authors: Xishan Xiong; Yangliang Ye; Lili Fu; Bing Dai; Jieqiong Liu; Jieshuang Jia; Jing Tang; Lin Li; Li Wang; Jianhua Shen; Changlin Mei
Journal: Invest New Drugs Date: 2008-08-13 Impact factor: 3.850

Design and synthesis of N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5- methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]glycine [Muraglitazar/BMS-298585], a novel peroxisome proliferator-activated receptor alpha/gamma dual agonist with efficacious glucose and lipid-lowering activities.

1. Discovery and Preclinical Evaluation of BMS-711939, an Oxybenzylglycine Based PPARα Selective Agonist.

Review 2. PPARgamma as a new therapeutic target in inflammatory bowel diseases.

3. Discovery of a Novel Selective Dual Peroxisome Proliferator-Activated Receptor α/δ Agonist for the Treatment of Primary Biliary Cirrhosis.

4. Comparative gene expression profiles induced by PPARγ and PPARα/γ agonists in human hepatocytes.

5. Antitumor activity of a novel series of alpha-aryloxy-alpha-methylhydrocinnamic acid derivatives as PPAR gamma agonists against a panel of human cancer cell lines.

6. Pyrimidinyl-arylpropionic acid derivatives: viable resources in the development of new antineoplastic agents.

7. The PPAR-Platelet Connection: Modulators of Inflammation and Potential Cardiovascular Effects.

Review 8. Organic carbamates in drug design and medicinal chemistry.

Review 9. Peroxisome Proliferator-Activated Receptors and the Heart: Lessons from the Past and Future Directions.

10. Anti-inflammatory properties of a dual PPARgamma/alpha agonist muraglitazar in in vitro and in vivo models.